1,（1→3）-β-D-glucan,1,743
A,acidic electrolyzed water,1025
A,acidic hypochloritde solution,1025
A,acute epiglottitis,336
A,acute leukemia,1078
A,acute myeloid leukemia,618
A,acute necrotizing encephalopathy,778
A,acyclovir,341
A,adenovirus type 7,1217
A,adherence,1104
A,adhesion,7
A,adjuvant,1145
A,adult,640
A,adverse effect,1123
A,Aeromonas sobria,257
A,Aeromonas hydrophila,1074
A,AIDS,351,609,702,1227,1232
A,airport quarantine,110
A,amphotericin B,783
A,anaerobe,675
A,animal model,7,122,1082
A,anti-E. coli O157 LPS antibody,451
A,anti-HIV therapy,909
A,anti-LPS antibody,772
A,anti-rotavirus IgA,305
A,antibiotic,239,255,884,1054
A,antibiotic-associated diarrhea,467
A,antibody,239
A,antibody prevalence,578
A,antigen specific T cell response,1145
A,antimicrobial activity,694
A,aquatic environment,25
A,aseptic meningitis,138
A,Aspergillus niger,618
A,astrovirus,559,578
A,atypical pulmonary mycobacteriosis,728
A,automatical system,172
B,Babesia microti,1163
B,babesiosis,1163
B,bacterial meningitis,901
B,bacterial pneumonia,602
B,Bangladesh,918
B,Bartonella henselae,90,248,930,1241
B,Bifidobacterium breve YIT4064,305
B,BCG,658
B,β-defensin,156
B,β-lactam,1048
B,Beutin's blood agar,318
B,bicytopenia,244
B,blood transfusion,1163
B,bone marrow transplantation,144
B,booster phenomenon,766
B,Bordetella pertussis,239
B,brain abscess,783
B,breast milk,451
B,bronchial asthma,1165
B,bronchial washing,728
B,bronchioalveolar lavage,346
B,bronchopulmonary infection,675
B,bronchoscopic finding,346
C,cacao mass,694
C,Campylobacter fetus,86
C,candida antigen,743
C,candidiasis,1
C,cat scratch disease,90,248,930
C,catheter-related infection,1032
C,cattle,445
C,causative microorganism,884
C,CD11b,328
C,CD62L,328
C,cellulitis,1159
C,central venous catheter,1032
C,cervical intraepithelial neoplasia,233
C,chemiluminescence-enzyme-immuno-assay,205
C,childhood,901
C,children,130,1069,1177,1205
C,Chlamydia pneumonia,191
C,Chlamydia pneumoniae,70,457,1177
C,Chlamydia trachomatis,633,939
C,chloroquine,1099
C,cholecystitis,149
C,cholera,918
C,chronic granulomatous disease,783
C,clinical study,652
C,Clostridium butyricum,7
C,Clostridium difficile,467
C,colicin type,414,1130
C,colony count assay,156
C,colostrum,451
C,combination therapy,1048
C,community-acquired pneumonia,70,717,884
C,complement,877
C,compromised host,477
C,congenital rubella syndrome,1038
C,connective tissue disease,1123
C,cost of medication,689
C,Coxiella burnetii,1236
C,coxsackie A16 virus,749
C,coxsackie B3 virus,122
C,critical care center,743
C,CT scan,130
C,culture,1095
C,CVD419 locus,218
C,cytomegalovirus,144
C,cytomegalovirus infection,351
C,cytotoxity,1025
D,deep-seated mycosis,1,743
D,deer,1140
D,definitive type 104,1087
D,dexamethasone,664
D,diarrheagenic Escherichia coli,1104
D,disinfection,1019
D,dissemination,341
D,double infection,939
D,drug resistance,414,1087,1210
D,drug susceptibility test,1099
E,eaeA gene,218
E,EB virus,702
E,echovirus,138
E,egg,437
E,elderly,43,298,689,1042,1153
E,ELISA,70,457,578,593,772
E,empyema,477
E,endophthalmitis,935
E,endoscope,1019
E,endotoxin,1222
E,enrichment broth,722
E,Entamoeba histolytica,626
E,enteric pathogen,110
E,enteroaggregative Escherichia coli,1104
E,Enterococcus gallinarum,1078
E,enterohemolysin,218,255
E,enterohemorrhagic Escherichia coli（EHEC）,53,213,255,318
E,enterohemorrhagic Escherichia coli O157：H7,7,694,1054,1082
E,enterohemorrhagic Escherichia coli O26（EHEC O26）,407
E,enterotoxin,893
E,enterovirus 71,749
E,enzyme immunoassay（EIA）,35,213,421,467,633,1153
E,enzyme-linked fluorescent assay,681
E,epidemic,138
E,epidemiological marker,179,923
E,epidemiology,35,97,225,437,1194,1217
E,Escherichia coli,1110
E,Escherichia coli O157,772
E,Escherichia coli O157：H7,451,593,722
E,extended-spectrum β-lactamase（ESBL）,1110
F,fever of unknown origin（FUO）,62,248
F,food handlers,758
F,food poisoning,179,356,787
F,fosfomycin（FOM）,291
F,fractional inhibitory concentration（FIC）index,291
G,gastroenteritis,578
G,germfree mouse,1054
G,granular lymphocyte-proliferative disorder,702
G,growth condition,565
H,H2O2,328
H,Haemophilus influenzae type b,336,901
H,HAV,559
H,healthy carrier,758
H,Helicobacter pylori,15,565,1019
H,hemagglutination inhibition test,734
H,hemolytic uremic syndrome,593
H,hemorrhagic colitis,593
H,heterogeneously vancomycin-resistant Staphylococcus aureus,1048
H,histoplasmosis,1227
H,HIV,1183
H,HIV screening kit,681
H,HIV-1,1241
H,homeless,717
H,human papillomavirus（HPV）,233
H,hybrid capture human papillomavirus DNA assay,233
H,hypoxemia,640
I,I-system,1032
I,immunoassay,1064,1069,1199
I,immunocompromised host,144,1205
I,immunoglobulin G,122
I,imported infection,76
I,indirect fluorescent antibody test,90,1241
I,indirect immunofluorescent assay,734
I,infection,197,1130
I,infectious lymphocyst,473
I,infectious thrombophlebitis,86
I,influenza,689,1153
I,influenza A virus,778
I,influenza B virus,253
I,influenza epidemic,1042
I,influenza vaccine,1042
I,influenza virus,1064,1069,1084,1199
I,intradermal immunization,600
I,isolation,25
J,Japan,83
J,Japanese encephalitis,97
K,Kaposi's sarcoma,351
K,Klebsiella pneumoniae,935,1110
L,lactic acid,163
L,lactic acidosis,1232
L,Legionella,25,421
L,Leptotrombidinm pallidum,1194
L,leukocyte,877
L,liver abscess,935
L,LPS antibody,593
L,lung cancer,187
M,malignant lymphoma,341,609
M,mannitol,707
M,measles,104,640
M,mechanical ventilation,570
M,mentally retarded patient,626
M,MIC breakpoint,1187
M,MIC,149
M,micro immunofluorescence test,457
M,microaerophilic gas generator,1095,1099
M,microbicidal activity,1025
M,microdilution broth method,565
M,microorganism,1165
M,microplate immunofluorescence antibody technique,457
M,milk antibody,122
M,minimal broth,722
M,mixed infection,602,614
M,Moraxella catarrhalis,311,361
M,MRSA,225,584,606
M,MT-2 assay,909
M,multicenter screening,70
M,mycobacteria,172
M,mycobacteria growth indicator tube（MGIT）,172
M,Mycobacterium avium complex,728
M,Mycobacterium gordonae,482
M,Mycoplasma hominis,646
M,Mycoplasma pneumoniae,939,1177
M,Mycoplasma pneumoniae pneumonia,602
M,myelodysplastic syndrome,257
M,myositis,76
N,nasal aspirate,1064
N,nasal inhalation,429
N,nasal inoculation,1145
N,necrotizing myofascitis,1074
N,neonatal exanthematous disease,893
N,neonatal TSS-like exanthematous disease,606
N,neuraminidase,1084
N,new practical criteria,62
N,Nocardia farcinica,477
N,nontuberculous mycobacteriosis,482
N,norfloxacin（NFLX）,291
N,nosocomial infection,298,361
N,nosocomial pneumonia,884
N,nucleoside reverse transcriptase inhibitor,1232
O,O-serotype,53
O,opportunistic infection,1227
O,Orientia tsutsugamushi,1194
O,ornithine,414
O,ornithine decarboxylase,707
O,otomycosis,618
O,outbreak,253,356,361,437,1130
O,oyster,559
P,p24 antigen,205,681
P,panipenem/betamipron,43
P,paradoxical effect,163
P,parainfluenza 3 virus,298
P,particle agglutination test,1183
P,parvovirus B19,244
P,Pasteurella multocida subsp. septica,623
P,PCR,144,346,559,626
P,penicillin-G dry susceptibility,1116
P,penicillin resistant Streptococcus pneumoniae（PRSP）,584,1187
P,peptide antigen,633
P,pertussis vaccine,1145
P,pH,163
P,phage type 1,437
P,phagocytic bactericidal activity,239
P,pharyngeal colonization,429
P,plasmid,225,1110
P,plasmid profile,923
P,Plasmodium falciparum,83,1095,1099
P,pneumoconiosis,311
P,Pneumocystis carinii pneumonia,1123
P,pneumonia,570
P,polymorphonuclear leukocyte,239
P,positive antibody rate,1038
P,povidone-iodine,429
P,pre-exposure immunization,600
P,prevention,305
P,primary complex,658
P,primary septicemia,149
P,probiotic,7
P,procalcitonin,197
P,prognosis,1205
P,prognostic factor,570
P,protease inhibitor,702
P,Pseudomonas aeruginosa,291
P,pulmonary cryptococcosis,187
P,pulmonary function,640
P,pulsed-field gel electrophoresis（PFGE）,20,179,218,225,923
P,purulent meningitis,336,664
Q,Q fever,1236
Q,quinolone,1116
R,rabies,600
R,radial diffusion assay,156
R,radioimmunoassay（RIA）,156
R,random amplified polymorphic DNA（RAPD）,923
R,rapid antigen detection,336
R,rapid diagnosis,421,901,1064,1069,1084,1153,1199
R,rapid method,213
R,reevaluation,1183
R,respiratory infection,43,1165
R,respiratory tract infection,1177,1187
R,restriction enzyme,749
R,restriction enzyme analysis（REA）,361,311
R,restriction enzyme assay,1217
R,reverse-transcription PCR（RT-PCR）,35,156,749
R,rhamnose,407
R,rhamnose MacConkey medium,407
R,risk factor,149
R,rotavirus,35,305
R,RS virus,104
R,rubella vaccine,1038
R,rubella virus,734
S,salmon roe,20
S,Salmonella serovar Hadar,1210
S,Salmonella,758
S,Salmonella Enteritidis,437
S,Salmonella Oranienburg,787
S,Slmonella serovar Typhimurium,1087
S,schistosomiasis,614
S,screening,1183
S,secondary fever,664
S,semi-microtest,1099
S,sepsis,197,606,787,1074,1078,1205
S,septic arthritis,336
S,septic shock,257
S,serological criteria,457
S,serotype,35,445,1140
S,serum antibody,1082
S,serum IgG antibody,90
S,sexually transmitted diseases,233
S,Shiga toxin-producing Escherichia coil（STEC）,20,213
S,Shigatoxin（STx）,213
S,Shigella,758
S,Shigella sonnei,414,707,923,1130
S,silkworm larvae plasma,1222
S,single photon emission computed tomography（SPECT）,609
S,small round structured virus（SRSV）,356,559
S,sporadic diarrhea,53,1104
S,Staphylococcus aureus,291,328,877,893
S,steroid inhalation,1165
S,steroid pulse therapy,1205
S,Streptococcus agalactiae,163
S,Streptococcus pneumoniae,717,901,1116
S,sudden death,1159
S,sulfamethoxazole-trimethoprim（ST）,1123
S,superantigen,893
S,surveillance,97
S,susceptibility test,565
S,syncytium inducing virus,909
S,systemic inflammatory response syndrome（SIRS）,197
S,systemic lupus erythematosus（SLE）,191,477,1123
T,teicoplanin,1048
T,thalamic hemorrhage,778
T,TNF-α,877
T,tolerance,163
T,toxic shock syndrome toxin-1（TSST-1）,893
T,toxin A,467
T,toxin type,445,1140
T,transbronchial lung biopsy,728
T,transtracheal aspiration,675
T,traveller's diarrhoea,110
T,trichinellosis,76,614
T,tuberculin test,658
T,tuberculosis,130,658,766
T,two-step tuberculin test,766
U,upper genital tract,646
U,urinary antigen,421
U,urosepsis,652
U,uterine myoma,244
V,vaccination rate,1038
V,vaccine efficacy,1042
V,vanB,473
V,vancomycin,1048
V,vancomycin-resistant Enterococcus（VRE）,473
V,varicella pneumonia,346
V,varicella-zoster virus,341
V,vero（cyto）toxin-producing Escherichia coli（VTEC）,53,318,445,1140
V,verotoxin,694,1054
V,verotoxin-producing Eschericia coli（VTEC）O121：H19,218
V,viable but nonculturable,15
V,Vibrio cholerae O139,918
V,Vibrio parahaemolyticus,179
V,Vibrio vulnificus,149,1159
V,virulence gene,1104
V,vitamin A,104
W,Waldenstrom's macroglonbulinemia,86
W,window period,205,681
Z,zoonosis,623,930